BUY, SELL, HOLD (2)

NVO Stock Hits New High on Sunny Full-Year Forecast

The firm's operating profit, on the other hand, missed estimates

Digital Content Manager
Nov 1, 2019 at 10:23 AM
facebook X logo linkedin


Pharma stock Novo Nordisk (NYSE:NVO) is trading higher after the firm lifted its full-year sales outlook, and announced its Ozempic diabetes drug reached blockbuster status in the U.S. during its first nine months on the market, generating $1.03 billion in sales -- beating analysts' expectations. Some of these gains, however, have been tamped by the Eli Lilly (LLY) competitor's third-quarter operating profit, which missed analysts' estimates.

At last check, NVO is up 3.8% at $57.28, earlier hitting a new annual high of $57.29. Since a brief pullback to familiar support at its 200-day moving average in late September, the stock has been climbing up the charts, notching a 6.8% gain for October, and a nearly 24% gain for the year.

Consensus among the brokerage bunch is split, with three analysts giving NVO stock a "strong buy" rating, and three saying it's a "hold" or worse. What's more, the 12-month average target price of $57.90 is just a slim 1.1% premium to current levels. 

The options pits, on the other hand, are overwhelmingly bullish. Over 180 calls have been bought to open for every put on the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). Novo Nordisk's 10-day put/call volume ratio of 186.32 sits higher than all but 3% of similar readings from the past year, indicating that this rate of call buying relative to put buying is highly unusual. 

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.